The sheer amount of available apps allows users to customize smartphones to match their personality and interests. As one of the first large-scale studies, the impact of personality traits on mobile app adoption was examined through an empirical study involving 2043 Android users. A mobile app was developed to assess each smartphone user's personality traits based on a state-of-the-art Big Five questionnaire and to collect information about her installed apps. The contributions of this work are twofold. First, it confirms that personality traits have significant impact on the adoption of different types of mobile apps. Second, a machine-learning model is developed to automatically determine a user's personality based on her installed apps. The predictive model is implemented in a prototype app and shows a 65% higher precision than a random guess. Additionally, the model can be deployed in a non-intrusive, low privacy-concern, and highly scalable manner as part of any mobile app.

Understanding how environmental factors impact COVID-19 transmission informs global containment efforts. We studied the relative risk of COVID-19 due to weather and ambient air pollution. We estimated the daily reproduction number at 3,739 global locations, controlling for the delay between infection and detection, associating those with local weather conditions and ambient air pollution. Controlling for location-specific fixed effects and local policies, we found a negative relationship between the estimated reproduction number and temperatures above 25 o C, a U-shaped relationship with outdoor ultraviolet exposure, and weaker positive associations with air pressure, wind speed, precipitation, diurnal temperature, SO 2 and ozone. We projected the relative risk of COVID-19 transmission due to environmental factors in 1,072 global cities. Our projections suggest warmer temperature and moderate outdoor ultraviolet exposure may offer a modest reduction in transmission; however, upcoming changes in weather alone will not be enough to fully contain the transmission of COVID-19.

Research has revealed both the benefits and harms of social media use, but the public has very little guidance on how best to use social media to maximize the benefits to their health and well-being while minimizing the potential harms. Given that social media is intricately embedded in our lives, and we now have an entire generation of social media natives, the time has come for a public health research agenda to guide not only the public’s use of social media but also the design of social media platforms in ways that improve health and well-being. In this viewpoint we propose such a public health agenda for social media research that is framed around three broad questions: (1) How much social media use is unhealthy and what individual and contextual factors shape that relationship; (2) What are ways social media can be used to improve physical and mental well-being; and (3) How does health (mis)information spread, how does it shape attitudes, beliefs and behavior, and what policies or public health strategies are effective in disseminating legitimate health information while curbing the spread of health misinformation? We also discuss four key challenges that impede progress on this research agenda: negative sentiment about social media among the public and scientific community, a poorly regulated research landscape, poor access to social media data, and the lack of a cohesive academic field. Social media has revolutionized modern communication in ways that bring us closer to a global society, but we currently stand at an inflection point. A public health agenda for social media research will serve as a compass to guide us toward social media becoming a powerful tool for the public good.

The grocery retail industry is encountering unique challenges and opportunities during the 2019 Novel Coronavirus (COVID-19). The pandemic led to various transformations in the food retail industry, including changes in consumer perception and behavior. Although the pandemic has a situational nature, these transformations could have both temporary and long-lasting effects on reforms of the grocery retail industry. We examined consumer retail grocery shopping behavior change during the pandemic using a national survey among 2500 U.S. adults. Survey results show that consumers now have higher expectations for in-store safety; they have reduced the frequency of store patronage, travel time, and in-store duration; they have shifted from regular shopping schedule and shopping destinations; and they have spent more per shopping trip. The increased spending at brick-and-mortar stores also paralleled with the expanded transactions across various types of online grocery shopping platforms. We further arrived at practical managerial implications in both the short term and long term for brick-and-mortar stores as well as online grocery vendors.

LBA292 Background: 1L treatment for pts with HER2−, mG/GEJ adenocarcinoma is typically chemotherapy and immunotherapy; an unmet need still exists. CLDN18.2 is expressed in normal gastric mucosa cells and retained in mG/GEJ tumor cells. In the FAST study, zolbetuximab, which targets CLDN18.2, prolonged survival of pts with LA unresectable or mG/GEJ adenocarcinoma when combined with chemotherapy. SPOTLIGHT (NCT03504397) is a phase 3 global, double-blind study comparing zolbetuximab + folinic acid, 5-FU, and oxaliplatin (mFOLFOX6) vs placebo + mFOLFOX6 as 1L treatment for pts with CLDN18.2+/ HER2−, LA unresectable or mG/GEJ adenocarcinoma. Methods: Previously untreated pts with CLDN18.2+ (moderate-to-strong membrane staining in ≥75% tumor cells by IHC)/HER2− LA unresectable or mG/GEJ adenocarcinoma were randomized 1:1 to zolbetuximab IV 800 mg/m2 (cycle [C] 1, day [D] 1) followed by 600 mg/m2 (C1D22, and every 3 weeks in later cycles) + mFOLFOX6 IV (D1, 15, 29) for four 42-day cycles vs placebo + mFOLFOX6; pts without PD continued for >4 cycles with zolbetuximab or placebo, + folinic acid and 5-FU at investigator’s discretion until PD or discontinuation criteria were met. The primary endpoint (EP) was PFS per RECIST v1.1 by IRC. Secondary EPs included OS, ORR, and safety. Differences in efficacy between treatment arms were tested by stratified log rank tests; OS was tested if PFS was significant. Results: Among 2735 pts screened, 565 pts were randomized 1:1 to zolbetuximab + mFOLFOX6 (N = 283) or placebo + mFOLFOX6 (N = 282). PFS was statistically significantly improved with zolbetuximab + mFOLFOX6 (median 10.61 vs 8.67 mo, HR 0.751, P=0.0066; Table). OS was also significantly improved (median 18.23 vs 15.54 mo, HR 0.750, P=0.0053, < 0.0135 as boundary; Table). ORR was similar between treatment arms. Most common TEAEs with zolbetuximab + mFOLFOX6 were nausea (82.4% vs 60.8% in zolbetuximab vs placebo arms), vomiting (67.4% vs 35.6%), and decreased appetite (47.0% vs 33.5%); the incidences of serious TEAEs were similar between both arms (44.8% vs 43.5%). Conclusions: Targeting CLDN18.2 with 1L zolbetuximab combined with mFOLFOX6 statistically significantly prolonged PFS and OS in pts with CLDN18.2+/ HER2−, LA unresectable or mG/GEJ adenocarcinoma. TEAEs were consistent with previous studies. Zolbetuximab + mFOLFOX6 may be a new option for these pts. Funding source: This study was funded by Astellas Pharma Inc. Medical writing support, conducted in accordance with Good Publication Practice (GPP 2022) and the International Committee of Medical Journal Editors (ICMJE) guidelines, was provided by Ann Ferguson, PhD, of Oxford PharmaGenesis Inc., Newtown, PA, USA, and funded by Astellas Pharma Inc. Clinical trial information: NCT03504397 . [Table: see text]